Donor Derived CD19 CAR-T Cells in the Treatment of R/R B-cell Acute Lymphoblastic Leukemia

This study tests a new type of immune cell therapy — CAR-T cells derived from a donor — to treat B-cell acute lymphoblastic leukemia (a fast-growing blood cancer) that has come back or not responded to chemotherapy. This approach is used when a patient's own immune cells cannot be used. **You may be eligible if...** - You are 18 or older and have been diagnosed with B-cell acute lymphoblastic leukemia - Your cancer has relapsed or did not respond after chemotherapy - Standard options such as your own CAR-T cells are not available or did not work - Your cancer cells have a marker called CD19 **You may NOT be eligible if...** - You have serious liver, heart, or lung problems - You have an active uncontrolled infection - Your blood counts are too low Talk to your doctor to see if this trial is right for you.